

10/01/01
1059 U.S. PTO

Please type a plus sign (+) inside this box → +

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Attorney Docket No. SHUTT-1 C1

First Inventor Reuben MATALON et al.

Title ASPARTOACYLASE GENE, PROTEIN, AND METHODS OF SCREENING FOR MUTATIONS ASSOCIATED WITH CANAVAN DISEASE

Express Mail Label No.

S PTO

09/965807

10/01/01

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
- Applicant claims small entity status.
See 37 CFR 1.27.
- Specification [Total Pages 50]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- Drawing(s) (35 U.S.C.113) [Total Sheets 13]
- Oath or Declaration [Total Pages 3]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR 1.63 (d))
(for a continuation/divisional with Box 18 completed)
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- Application Data Sheet. See 37 CFR 1.76

ADDRESS TO:Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (*Appendix*)
8. Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all necessary*)
 - a. Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. paper
 - c. Statements verifying identity of above copies

ACCOMPANYING APPLICATIONS PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 C.F.R. §3.73(b) Statement Power of Attorney (*when there is an assignee*)
11. English Translation Document (*if applicable*)
12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503) (*Should be specifically itemized*)
15. Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. Other: _____

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP)

of prior application No: 08/128,020 / 9/29/93

Prior application information: Examiner G. Bugaisky

Group / Art Unit: 1814

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.**17. CORRESPONDENCE ADDRESS** Customer Number or Bar Code Label

23599

PATENT TRADEMARK OFFICE

or Correspondence address below

Name	Anthony J. Zelano, Esq. Millen, White, Zelano & Branigan, P.C.				
Address	2200 Clarendon Blvd., Suite 1400				
City	Arlington	State	VA	Zip Code	22201
Country	U.S.A.	Telephone	703/243-6333	Fax	703/243-6410

Name (Print/Type)	Anthony J. Zelano	Registration No. (Attorney/Agent)	27,969
Signature			Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

10/10/01
1059 U.S. PTO

PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$)

\$370.00

Complete if Known

Application Number	Cont. of USSN 08/128,020
Filing Date	October 1, 2001
First Named Inventor	Reuben Matalon et al.
Examiner Name	G. Bugaisky
Group / Art Unit	1814

Attorney Docket No. SHUTT-1 C1

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number	13-3402
Deposit Account Name	Millen, White, Zelano & Branigan, P.C.
<input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	

2. Payment Enclosed:
 Check Credit card Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Entity Fee (\$)	Small Entity Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	\$370.00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	
SUBTOTAL (1)					(\$)
					370.00

2. EXTRA CLAIM FEES

Total Claims	14	-20**	=	0	X	9	=	0	Extra Claims	Fee from below	Fee Paid
Independent Claims	3	-3**	=	0	X	42	=	0			
Multiple Dependent					X						

Large Entity Fee Code	Entity Fee (\$)	Small Entity Fee Code	Entity Fee (\$)	Fee Description		
103	18	203	9	Claims in excess of 20		
102	84	202	42	Independent claims in excess of 3		
104	280	204	140	Multiple dependent claim, if not paid		
109	84	209	42	** Reissue independent claims over original patent		
110	18	210	9	** Reissue claims in excess of 20 and over original patent		
SUBTOTAL (2)					(\$)	0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES	Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105	130	205	65 SurchARGE - late filing fee or oath	
127	50	227	25 SurchARGE - late provisional filing fee or cover sheet.	
139	130	139	130 Non-English specification	
147	2,520	147	2,520 For filing a request for reexamination	
112	920*	112	920* Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840* Requesting publication of SIR after Examiner action	
115	110	215	55 Extension for reply within first month	
116	400	216	200 Extension for reply within second month	
117	920	217	460 Extension for reply within third month	
118	1,440	218	720 Extension for reply within fourth month	
128	1,960	228	980 Extension for reply within fifth month	
119	320	219	160 Notice of Appeal	
120	320	220	160 Filing a brief in support of an appeal	
121	280	221	140 Request for oral hearing	
138	1,510	138	1,510 Petition to institute a public use proceeding	
140	110	240	55 Petition to revive – unavoidable	
141	1,280	241	640 Petition to revive – unintentional	
142	1,280	242	640 Utility issue fee (or reissue)	
143	460	243	230 Design issue fee	
144	620	244	310 Plant issue fee	
122	130	122	130 Petitions to the Commissioner	
123	130	123	130 Petitions related to provisional applications	
126	180	126	180 Submission of Information Disclosure Stmt	
581	40	581	40 Recording each patent assignment per property (times number of properties)	
146	740	246	370 Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370 For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370 Request for Continued Examination (RCE)	
169	900	169	900 Request for expedited examination of a design application	
Other fee (specify) _____				

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

(\$)

SUBMITTED BY						Complete (if applicable)	
Name (Print/Type)	Anthony J. Zelano, Esq.	Registration No. Attorney/Agent)	27,969	Telephone	703.243.6333		
Signature				Date	October 1, 2001		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Reuben MATALON et al.

Serial No.: TBA

Examiner: G. Bugaishy

Filed: October 1, 2001

Group Art Unit: 1814

For: APARTOACYLASE GENE, PROTEIN, AND METHODS OF SCREENING FOR
MUTATIONS ASSOCIATED WITH CANAVAN DISEASE


REQUEST FOR TRANSFER OF CRF

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The paper copy of the Sequence Listing for this application (Cont. of USSN 08/128,020), is identical to the computer readable copy of the Sequence Listing filed in application, 08/128,020 on 11/29/93. In accordance with 37 CFR 1.821(e), please use the last-filed computer-readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing is included in a separately filed amendment, for incorporation into the specification.

Respectfully submitted,



Anthony J. Zelano, Esq.
Atty. Reg. No. 27,969
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon, Suite 1400
Arlington, VA 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SHUTT-1 C1

Filed: October 1, 2001

jc997 U.S. PTO
09/965807
10/01/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Reuben MATALON et al. : BOX SEQUENCE
Serial No.: 08/128,020 :
Filed: September 29, 1993 :

For: ASPARTOACYLASE GENE, PROTEIN, AND METHODS OF SCREENING
FOR MUTATIONS ASSOCIATED WITH CANAVAN DISEASE

**RESPONSE TO NOTICE TO COMPLY
WITH SEQUENCE DISCLOSURE REQUIREMENTS**

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

SIR:

In response to the Notice to Comply with Sequence Disclosure Requirements dated July 23, 1993, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 6, line 1: After "nucleotide", insert -- (SEQ ID NO:1) -- and
After "acid", insert -- (SEQ ID NO:2) --;
line 11: After "(HLASP)", insert -- (SEQ ID NO:2) --;
line 12: After "(BASPCDN)", insert -- (SEQ ID NO:4) --;
line 16: After "sequence", insert -- (SEQ ID NO:3) --; and
line 35: After the sequence, insert -- (SEQ ID NO:5) --.

Page 7, line 1: Before "and", insert -- (SEQ ID NO:6) --;
line 2: Before "primers", insert -- (SEQ ID NO:7) --;
line 13: After the sequence, insert -- (SEQ ID NO:5) --;
line 15: Before "and", insert -- (SEQ ID NO:8) --; and
line 16: Before "primers.", insert -- (SEQ ID NO:9) --.

Page 9, line 4: Before "and", insert -- (SEQ ID NO:10) -- and
Before "in", insert -- (SEQ ID NO:11) --; and
line 10: Before "sequence", insert -- (SEQ ID NO:12) --.

Between Pages 25 and 26: Insert the attached new pages 25i-25ix.

Page 27, line 1: After the sequence, insert -- (SEQ ID NO:13) --;
line 2: After the sequence, insert -- (SEQ ID NO:14) --;
line 3: After the sequence, insert -- (SEQ ID NO:15) --; and
line 4: After the sequence, insert -- (SEQ ID NO:16) --.

Page 28, line 3: Before "and", insert -- (SEQ ID NO:17) --;
line 4: After the sequence, insert -- (SEQ ID NO:18) --; and
line 16: After the sequence, insert -- (SEQ ID NO:19) --.

Page 30, line 4: After the sequence, insert -- (SEQ ID NO:5) --;
line 6: After the sequence, insert -- (SEQ ID NO:20) --;
line 7: After the sequence, insert -- (SEQ ID NO:21) --;
line 12: After the sequence, insert -- (SEQ ID NO:6) --;
line 13: After the sequence, insert -- (SEQ ID NO:7) --;
line 20: After the sequence, insert -- (SEQ ID NO:8) --; and
line 21: After the sequence, insert -- (SEQ ID NO:21) --.

Page 31, line 1: After the sequence, insert -- (SEQ ID NO:22) --;
line 2: After the sequence, insert -- (SEQ ID NO:23) --;
line 26: After "GGTHGNE,", insert -- (SEQ ID NO:10) -- and
After "DCTV", insert -- (SEQ ID NO:24) --;
line 27: After "VNEAAYY", insert -- (SEQ ID NO:11) --; and
line 28: After "GXXHG/AXE/D,", insert -- (SEQ ID NO:25) --,
After "DXXF/V", insert -- (SEQ ID NO:26) -- and
After "VXEXXXY", insert -- (SEQ ID NO:27) --.

IN THE CLAIMS:

10. (Amended.) A nucleic acid molecule of claim 8, having the sequence
CTTCTGAATTGCAGAAATCA (HASP9) (SEQ ID NO:20) or
GTAAGACACCGTGTAAAGATG (HASPC7) (SEQ ID NO:21).

11. (Amended.) A nucleic acid molecule of claim 9, having the sequence
F→CCGGGATGAAAATGGAGAA (HASP14F) (SEQ ID NO:6) or
R→ACCGTGTAAGATGTAAAGC (HASPC7R) (SEQ ID NO:7),
wherein F and R are M13 universal and/or reverse primer tags.

35. (Amended.) A method of claim 33, wherein the probe is selected from the sequences

CTTCTGAATTGCAGAAATCA (HASP9) (SEQ ID NO:20),

GTAAGACACCGTGTAAAGATG (HASPC7) (SEQ ID NO:21),

F→CCGGGATGAAAATGGAGAA (HASP14F) (SEQ ID NO:6) or

R→ACCGTGTAAGATGTAAGC (HASPC7R) (SEQ ID NO:7),

wherein F and R are M13 universal and/or reverse primer tags.

IN THE DRAWINGS:

Please replace Figures 7(f) and 7(g) with the attached proposed new Figures 7(f) and 7(g).

R E M A R K S

The amendments are for the purpose of putting the application in compliance with 37 C.F.R. §1.821 – §1.825, as stated in the Office Action. The proposed new Figures 7(f) and 7(g) delete extraneous amino acid sequences corresponding to computer-generated read-through of the coding sequence.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing are the same.

I hereby state that the submission, filed in accordance with 37 C.F.R. §1.1821(g), herein does not include new matter.

Respectfully submitted,

Diana Hamlet-King (Reg. No. 33,302)
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
(703) 243-6333

Filed: November 29, 1993

DHK:kdp
kdp72:shutt1.rsp